Abiopharma

General Announcement: Net Asset Value ("NAV") as of 24 August 2026

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

TGS Awarded Extension to Largest Seismic Acquisition Project Offshore Indonesia

Dividend

Woodside Energy Half-Year Report for Period Ended 30 June 2026

The company’s outstanding obligations as of 30.6.26, by maturity dates

Q2/semi-annual report for 2026

General Announcement: Auditor Not Seeking Re-Appointment at AGM for FY2025

The company’s liability position as of June 30, 2026, by maturity dates

Q2 / Semi-annual report for 2026

General Announcement: Disclaimer of Opinion in the Financial Statements for FY2025 and Material Variances

Scrip Election/ Distribution/ DRP:

General Announcement: Press Release - Centurion Launches Inaugural Sustainability Notes

General Announcement: Clarification Ahead of the Information Session